Effective co-delivery of doxorubicin and curcumin using a glycyrrhetinic acid-modified chitosan-cystamine-poly(ε-caprolactone) copolymer micelle for combination cancer chemotherapy

Zhang, 2015, Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy, Biomaterials, 67, 104, 10.1016/j.biomaterials.2015.07.027 Greco, 2009, Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines, Adv. Drug Delivery Rev., 61, 1203, 10.1016/j.addr.2009.05.006 Broxterman, 2005, Anticancer therapeutics: addictive targets, multi-targeted drugs, new drug combinations, Drug Resist. Updates, 8, 183, 10.1016/j.drup.2005.07.002 Jhaveri, 2014, Stimuli-sensitive nanopreparations for combination cancer therapy, J. Controlled Release, 190, 352, 10.1016/j.jconrel.2014.05.002 Al-Lazikani, 2012, Combinatorial drug therapy for cancer in the post-genomic era, Nat. Biotechnol., 30, 679, 10.1038/nbt.2284 Hu, 2012, Nanoparticle-based combination therapy toward overcoming drug resistance in cancer, Biochem. Pharmacol., 83, 1104, 10.1016/j.bcp.2012.01.008 Wang, 2015, Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells, Biomaterials, 72, 74, 10.1016/j.biomaterials.2015.08.048 Huang, 2010, Glycyrrhetinic acid-modified poly(ethylene glycol)-b-poly(γ-benzyl l-glutamate) micelles for liver targeting therapy, Acta Biomater., 6, 3927, 10.1016/j.actbio.2010.04.021 Zhang, 2008, Nanoparticles in medicine: therapeutic applications and developments, Clin. Pharmacol. Ther., 83, 761, 10.1038/sj.clpt.6100400 Wagner, 2006, The emerging nanomedicine landscape, Nat. Biotechnol., 24, 1211, 10.1038/nbt1006-1211 Duncan, 2006, Polymer conjugates as anticancer nanomedicines, Nat. Rev. Cancer, 6, 688, 10.1038/nrc1958 Ferrari, 2005, Cancer nanotechnology: opportunities and challenges, Nat. Rev. Cancer, 5, 161, 10.1038/nrc1566 Park, 2002, Liposome-based drug delivery in breast cancer treatment, Breast Cancer Res., 4, 10.1186/bcr432 Wang, 2013, Glutathione-triggered off-on release of anticancer drugs from dendrimer-encapsulated gold nanoparticles, J. Am. Chem. Soc., 135, 9805, 10.1021/ja402903h Guo, 2012, The intracellular controlled release from bioresponsive mesoporous silica with folate as both targeting and capping agent, Nanoscale, 4, 3577, 10.1039/c2nr30425b Lee, 2010, Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics, Angew. Chem., 122, 8390, 10.1002/ange.201002639 Park, 2009, Enzyme responsive nanocontainers with cyclodextrin gatekeepers and synergistic effects in release of guests, J. Am. Chem. Soc., 131, 16614, 10.1021/ja9061085 He, 2012, A light-responsive reversible molecule-gated system using thymine-modified mesoporous silica nanoparticles, Langmuir, 28, 4003, 10.1021/la2047504 Mura, 2013, Stimuli-responsive nanocarriers for drug delivery, Nat. Mater., 12, 991, 10.1038/nmat3776 Shi, 2015, Co-delivery of docetaxel and chloroquine via PEO-PPO-PCL/TPGS micelles for overcoming multidrug resistance, Int. J. Pharm., 495, 932, 10.1016/j.ijpharm.2015.10.009 Mo, 2015, Controlled release and targeted delivery to cancer cells of doxorubicin from polysaccharide-functionalised single-walled carbon nanotubes, J. Mater. Chem. B, 3, 1846, 10.1039/C4TB02123A Wang, 2014, Acid-triggered drug release from micelles based on amphiphilic oligo(ethylene glycol)-doxorubicin alternative copolymers, J. Mater. Chem. B, 2, 7612, 10.1039/C4TB01231C Pommier, 2010, Their poisoning by anticancer and antibacterial drugs, Chem. Biol., 17, 421, 10.1016/j.chembiol.2010.04.012 Tacar, 2013, Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems, J. Pharm. Pharmacol., 65, 157, 10.1111/j.2042-7158.2012.01567.x Hortobagyi, 1979, Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG, Cancer, 44, 1955, 10.1002/1097-0142(197911)44:5<1955::AID-CNCR2820440559>3.0.CO;2-P Ilieva, 2014, Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany), Phytochem. Rev., 13, 459, 10.1007/s11101-014-9351-7 Shehzad, 2010, Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials, Arch. Pharm., 343, 489, 10.1002/ardp.200900319 Priyadarsini, 2009, Photophysics, photochemistry and photobiology of curcumin: studies from organic solutions, bio-mimetics and living cells, J. Photochem. Photobiol. C, 10, 81, 10.1016/j.jphotochemrev.2009.05.001 Zhongfa, 2012, Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice, Cancer Chemother. Pharmacol., 69, 679, 10.1007/s00280-011-1749-y Hamman, 2010, Chitosan based polyelectrolyte complexes as potential carrier materials in drug delivery systems, Mar. Drugs, 8, 1305, 10.3390/md8041305 Luo, 2014, Recent development of chitosan-based polyelectrolyte complexes with natural polysaccharides for drug delivery, Int. J. Biol. Macromol., 64, 353, 10.1016/j.ijbiomac.2013.12.017 Shukla, 2013, Chitosan-based nanomaterials: a state-of-the-art review, Int. J. Biol. Macromol., 59, 46, 10.1016/j.ijbiomac.2013.04.043 Mondrinos, 2006, Porogen-based solid freeform fabrication of polycaprolactone-calcium phosphate scaffolds for tissue engineering, Biomaterials, 27, 4399, 10.1016/j.biomaterials.2006.03.049 He, 2010, Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery, Int. J. Pharm., 397, 147, 10.1016/j.ijpharm.2010.06.029 Qiu, 2007, Self-assembled polyethylenimine-graft-poly(ε-caprolactone) micelles as potential dual carriers of genes and anticancer drugs, Biomaterials, 28, 4132, 10.1016/j.biomaterials.2007.05.035 Li, 2014, Intracellular redox potential-responsive micelles based on polyethylenimine-cystamine-poly(ε-caprolactone) block copolymer for enhanced miR-34a delivery, Polym. Chem., 6, 1952, 10.1039/C4PY01623H Saito, 2003, Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities, Adv. Drug Delivery Rev., 55, 199, 10.1016/S0169-409X(02)00179-5 Chou, 1984, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv. Enzyme Regul., 22, 27, 10.1016/0065-2571(84)90007-4 Noh, 2015, Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer, Biomaterials, 53, 763, 10.1016/j.biomaterials.2015.03.006 Liu, 2014, Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity, Mol. Pharm., 11, 1651, 10.1021/mp5000373 Pérez-Herrero, 2015, Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy, Eur. J. Pharm. Biopharm., 93, 52, 10.1016/j.ejpb.2015.03.018 Callaghan, 2014, Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy, Drug Metab. Dispos., 42, 623, 10.1124/dmd.113.056176 Stege, 2016, Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference cancer, Cancer. Gene Ther., 11, 699, 10.1038/sj.cgt.7700751 Mo, 2011, The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles, Biomaterials, 32, 4609, 10.1016/j.biomaterials.2011.03.005 Xiang, 2013, Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance, Mol. Pharm., 11, 145 Jelezova, 2015, Curcumin loaded pH-sensitive hybrid lipid/block copolymer nanosized drug delivery systems, Eur. J. Pharm. Sci., 78, 67, 10.1016/j.ejps.2015.07.005 Jardim, 2015, Physico-chemical characterization and cytotoxicity evaluation of curcumin loaded in chitosan/chondroitin sulfate nanoparticles, Mat. Sci. Eng. C, 56, 294, 10.1016/j.msec.2015.06.036 Maeda, 2001, The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting, Adv. Enzymol. Regul., 41, 189, 10.1016/S0065-2571(00)00013-3 Li, 2014, pH dual-sensitive polymeric vector for long-circulating and tumor-targeted siRNA delivery, Adv. Mater., 26, 8217, 10.1002/adma.201403877 Lock, 1992, Inhibition of p34cdc2 kinase activation, p34cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster cells exposed to etoposide, Cancer Res., 52, 1817